Neoplasms

All Conditions

Rare Diseases

Glioblastoma

Astrocytoma

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Etoposide

Temozolomide

Cisplatin

Etoposide phosphate

Enzyme Inhibitors

Etoposide 100mg/m2 d1-5 Cisplatin 20mg/mCisplatin d1-5

Etoposide Plus Cisplatin

Yahua Zhong, Phd

Jianyin Huang, MD

Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. The aim of this study is to compare the effect of Etoposide plus Cisplatin and Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma.

60 Patients with glioblastoma were recruited for this study based on the following eligibility criteria: Age between 18 and 70, performance status of 0-1 (Eastern Cooperative Oncology Group performance status), histologically confirmed MGMT gene promoter unmethylation glioblastoma, no cerebrospinal fluid and distant metastatic disease. All patients had adequate hematologic, hepatic, and renal function. Patients younger than 18 years; patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities were excluded.

60 patients were randomly divided into two groups and compared the difference of efficacy between the two groups

Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma

Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Newly Diagnosed MGMT Promotor Unmethylated Glioblastoma

The length of time from the date of diagnosis to death from cancer

the length of time after primary treatment for glioblastoma ends that the patient survives without any progression of glioblastoma.

Zhongnan Hospital

Respiratory Tract (Lung and Bronchial) Diseases

Small Cell Lung Carcinoma

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Small Cell Lung Cancer

Chemotherapy:etoposide plus lobaplatin (EL)

Chemotherapy:etoposide plus cisplatin (EP)

Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin

etoposide plus lobaplatin

Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin

etoposide plus cisplatin

ShengFa Su, PhD,MD

Bing Lu, MD

Shengfa Su, PhD,MD

This randomized phase II study compare survival outcomes and toxicity of two chemotherapy regimens (etoposide plus lobaplatin or etoposide plus cisplatin) in combination with concurrent thoracic radiation therapy (TRT) for limited stage small cell lung cancer.

Lobaplatin is a platinum complex with DNA alkylating activity that was developed by ASTA Medica (Degussa) for the treatment of cancer. Lobaplatin as the third-generation platinum antineoplastic agent, showed promising antineoplastic effects in variety of preclinical test tumor models. A randomized, multicenter phase III study showed that Lobaplatin plus etoposide (EL) regimen is not inferiority to cisplatin plus etoposide (EP) regimen in terms of PFS, the tolerance and QOL with EL regimen are better than that with EP regimen. Thus, we perform this study was to compare the efficacy and safety of EL and EP regimens concurrently with thoracic radiotherapy in patients with limited-stage SCLC.

Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer

A Randomized Phase II Trial of Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin in Combination With Concurrent Thoracic Radiotherapy for Patients With Limited Small-cell Lung Cancer

PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.

Overall survival is defined as the time interval from date of diagnosis to date of death from any cause

To assess and record nausea, vomiting, hematologic toxicity,radiation oesophagitis and other treantment complications by CTCAE v4.0

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma	NCT05694416	MGMT-Unmethylat...	Etoposide Plus ...	18 Years - 70 Years	Zhongnan Hospital
Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma	NCT05694416	MGMT-Unmethylat...	Etoposide Plus ...	18 Years - 70 Years	Zhongnan Hospital
Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer	NCT03613597	Small-cell Lung...	etoposide plus ... etoposide plus ...	18 Years - 75 Years	Guizhou Medical University

Spots Global Cancer Trial Database for etoposide plus cisplatin